Effect of α-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: A quantitative polymerase chain reaction study
Sera from 30 patients with community‐acquired, biopsy‐proven chronic non‐A, non‐B hepatitis (NANBH) were tested for antibodies to the C100 protein of hepatitis C virus (HCV). The 20 patients who showed reactivity in this assay were followed prospectively for 6 months, during which time seven were tr...
Gespeichert in:
| Veröffentlicht in: | Journal of medical virology 1991-06, Vol.34 (2), p.136-141 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 141 |
|---|---|
| container_issue | 2 |
| container_start_page | 136 |
| container_title | Journal of medical virology |
| container_volume | 34 |
| creator | Brillanti, S. Garson, J. A. Tuke, P. W. Ring, C. Briggs, M. Masci, C. Miglioli, M. Barbara, L. Tedder, R. S. |
| description | Sera from 30 patients with community‐acquired, biopsy‐proven chronic non‐A, non‐B hepatitis (NANBH) were tested for antibodies to the C100 protein of hepatitis C virus (HCV). The 20 patients who showed reactivity in this assay were followed prospectively for 6 months, during which time seven were treated with recombinant α‐interferon. HCV RNA was detected by “nested” polymerase chain reaction (PCR) in 19 of the 20 anti‐C100‐positive sera taken at the onset of the study and also in five of the ten anti‐Cl00‐negative sera. Pretreatment viraemia levels ranged from 2 × 103 to 2 × 108HCV genomesiml. After 6 months of interferon, elevated serum alanine aminotransferase (ALT) levels had fallen to normal in four of the seven treated patients. In each case the response to interferon was accompanied by either a disappearance of or a decline (1 log to 8 log reduction) in viraemia. HCV genome titres in the three nonresponders and in the 13 untreated anti‐C100‐positive patients did not change significantly over this 6 month period. These findings confirm the aetiological role of HCV in community‐acquired NANBH and suggest that quantitative PCR will become a valuable technique for monitoring the antiviral effect of interferon and other experimental treatments. |
| doi_str_mv | 10.1002/jmv.1890340213 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72094975</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72094975</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3533-be0c23f8a8eba5cc87e9e2939030bfc8d1d65297e4356e808345470d04e678653</originalsourceid><addsrcrecordid>eNqFkc1uEzEUhS0EKiGwZYfkBWLFBHs89tjskqi0oBY2QJeW47mjuMxPYnsC8y68BC_CM2GYqBGrrq5973fusXwQek7JghKSv7ltDwsqFWEFySl7gGaUKJEpUtKHaEZoITIhKH-MnoRwSwiRKs_P0BktqciVmKGf53UNNuK-xr9_Za6L4GvwfYfjFrzZjTgdt7Az0UUX8BofnDfQOoNdh23ftkPn4pgZux-chwrbbdI6i7u-y5av_5XVSf8WL_F-MF26pMYB8K5vxjb5BEhKk1Z6MDa65BniUI1P0aPaNAGeHescfXl3_nl9mV19uni_Xl5llnHGsg0Qm7NaGgkbw62VJSjIFUufQja1lRWtBM9VCQXjAiSRrOBFSSpSgCil4GyOXk17d77fDxCibl2w0DSmg34IusyJKlR5P0gFYZwk6zlaTKD1fQgear3zrjV-1JTov7nplJs-5ZYEL46bh00L1Qmfgkrzl8e5CdY0tTeddeEO41xJToqEqQn77hoY7zHVH66__veEbNK6EOHHndb4b1qUrOT65uOFXq1vrjlbXWrJ_gBtiMKG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16035029</pqid></control><display><type>article</type><title>Effect of α-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: A quantitative polymerase chain reaction study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Brillanti, S. ; Garson, J. A. ; Tuke, P. W. ; Ring, C. ; Briggs, M. ; Masci, C. ; Miglioli, M. ; Barbara, L. ; Tedder, R. S.</creator><creatorcontrib>Brillanti, S. ; Garson, J. A. ; Tuke, P. W. ; Ring, C. ; Briggs, M. ; Masci, C. ; Miglioli, M. ; Barbara, L. ; Tedder, R. S.</creatorcontrib><description>Sera from 30 patients with community‐acquired, biopsy‐proven chronic non‐A, non‐B hepatitis (NANBH) were tested for antibodies to the C100 protein of hepatitis C virus (HCV). The 20 patients who showed reactivity in this assay were followed prospectively for 6 months, during which time seven were treated with recombinant α‐interferon. HCV RNA was detected by “nested” polymerase chain reaction (PCR) in 19 of the 20 anti‐C100‐positive sera taken at the onset of the study and also in five of the ten anti‐Cl00‐negative sera. Pretreatment viraemia levels ranged from 2 × 103 to 2 × 108HCV genomesiml. After 6 months of interferon, elevated serum alanine aminotransferase (ALT) levels had fallen to normal in four of the seven treated patients. In each case the response to interferon was accompanied by either a disappearance of or a decline (1 log to 8 log reduction) in viraemia. HCV genome titres in the three nonresponders and in the 13 untreated anti‐C100‐positive patients did not change significantly over this 6 month period. These findings confirm the aetiological role of HCV in community‐acquired NANBH and suggest that quantitative PCR will become a valuable technique for monitoring the antiviral effect of interferon and other experimental treatments.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.1890340213</identifier><identifier>PMID: 1716296</identifier><identifier>CODEN: JMVIDB</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Enzyme-Linked Immunosorbent Assay ; Female ; HCV ; Hepacivirus - genetics ; Hepacivirus - immunology ; Hepatitis Antibodies - blood ; Hepatitis C - therapy ; Hepatitis C Antibodies ; hepatitis C virus ; Hepatitis, Chronic - therapy ; Human viral diseases ; Humans ; Infectious diseases ; interferon ; Interferon alpha-2 ; Interferon-alpha - therapeutic use ; Male ; Medical sciences ; Middle Aged ; NANBH ; non-B hepatitis ; PCR ; Polymerase Chain Reaction ; Recombinant Proteins ; RNA, Viral - blood ; sporadic non-A ; viraemia ; Viral diseases ; Viral hepatitis ; Viremia - therapy</subject><ispartof>Journal of medical virology, 1991-06, Vol.34 (2), p.136-141</ispartof><rights>Copyright © 1991 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3533-be0c23f8a8eba5cc87e9e2939030bfc8d1d65297e4356e808345470d04e678653</citedby><cites>FETCH-LOGICAL-c3533-be0c23f8a8eba5cc87e9e2939030bfc8d1d65297e4356e808345470d04e678653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjmv.1890340213$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjmv.1890340213$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5598504$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1716296$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brillanti, S.</creatorcontrib><creatorcontrib>Garson, J. A.</creatorcontrib><creatorcontrib>Tuke, P. W.</creatorcontrib><creatorcontrib>Ring, C.</creatorcontrib><creatorcontrib>Briggs, M.</creatorcontrib><creatorcontrib>Masci, C.</creatorcontrib><creatorcontrib>Miglioli, M.</creatorcontrib><creatorcontrib>Barbara, L.</creatorcontrib><creatorcontrib>Tedder, R. S.</creatorcontrib><title>Effect of α-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: A quantitative polymerase chain reaction study</title><title>Journal of medical virology</title><addtitle>J. Med. Virol</addtitle><description>Sera from 30 patients with community‐acquired, biopsy‐proven chronic non‐A, non‐B hepatitis (NANBH) were tested for antibodies to the C100 protein of hepatitis C virus (HCV). The 20 patients who showed reactivity in this assay were followed prospectively for 6 months, during which time seven were treated with recombinant α‐interferon. HCV RNA was detected by “nested” polymerase chain reaction (PCR) in 19 of the 20 anti‐C100‐positive sera taken at the onset of the study and also in five of the ten anti‐Cl00‐negative sera. Pretreatment viraemia levels ranged from 2 × 103 to 2 × 108HCV genomesiml. After 6 months of interferon, elevated serum alanine aminotransferase (ALT) levels had fallen to normal in four of the seven treated patients. In each case the response to interferon was accompanied by either a disappearance of or a decline (1 log to 8 log reduction) in viraemia. HCV genome titres in the three nonresponders and in the 13 untreated anti‐C100‐positive patients did not change significantly over this 6 month period. These findings confirm the aetiological role of HCV in community‐acquired NANBH and suggest that quantitative PCR will become a valuable technique for monitoring the antiviral effect of interferon and other experimental treatments.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>HCV</subject><subject>Hepacivirus - genetics</subject><subject>Hepacivirus - immunology</subject><subject>Hepatitis Antibodies - blood</subject><subject>Hepatitis C - therapy</subject><subject>Hepatitis C Antibodies</subject><subject>hepatitis C virus</subject><subject>Hepatitis, Chronic - therapy</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>interferon</subject><subject>Interferon alpha-2</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>NANBH</subject><subject>non-B hepatitis</subject><subject>PCR</subject><subject>Polymerase Chain Reaction</subject><subject>Recombinant Proteins</subject><subject>RNA, Viral - blood</subject><subject>sporadic non-A</subject><subject>viraemia</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>Viremia - therapy</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1uEzEUhS0EKiGwZYfkBWLFBHs89tjskqi0oBY2QJeW47mjuMxPYnsC8y68BC_CM2GYqBGrrq5973fusXwQek7JghKSv7ltDwsqFWEFySl7gGaUKJEpUtKHaEZoITIhKH-MnoRwSwiRKs_P0BktqciVmKGf53UNNuK-xr9_Za6L4GvwfYfjFrzZjTgdt7Az0UUX8BofnDfQOoNdh23ftkPn4pgZux-chwrbbdI6i7u-y5av_5XVSf8WL_F-MF26pMYB8K5vxjb5BEhKk1Z6MDa65BniUI1P0aPaNAGeHescfXl3_nl9mV19uni_Xl5llnHGsg0Qm7NaGgkbw62VJSjIFUufQja1lRWtBM9VCQXjAiSRrOBFSSpSgCil4GyOXk17d77fDxCibl2w0DSmg34IusyJKlR5P0gFYZwk6zlaTKD1fQgear3zrjV-1JTov7nplJs-5ZYEL46bh00L1Qmfgkrzl8e5CdY0tTeddeEO41xJToqEqQn77hoY7zHVH66__veEbNK6EOHHndb4b1qUrOT65uOFXq1vrjlbXWrJ_gBtiMKG</recordid><startdate>199106</startdate><enddate>199106</enddate><creator>Brillanti, S.</creator><creator>Garson, J. A.</creator><creator>Tuke, P. W.</creator><creator>Ring, C.</creator><creator>Briggs, M.</creator><creator>Masci, C.</creator><creator>Miglioli, M.</creator><creator>Barbara, L.</creator><creator>Tedder, R. S.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>199106</creationdate><title>Effect of α-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: A quantitative polymerase chain reaction study</title><author>Brillanti, S. ; Garson, J. A. ; Tuke, P. W. ; Ring, C. ; Briggs, M. ; Masci, C. ; Miglioli, M. ; Barbara, L. ; Tedder, R. S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3533-be0c23f8a8eba5cc87e9e2939030bfc8d1d65297e4356e808345470d04e678653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>HCV</topic><topic>Hepacivirus - genetics</topic><topic>Hepacivirus - immunology</topic><topic>Hepatitis Antibodies - blood</topic><topic>Hepatitis C - therapy</topic><topic>Hepatitis C Antibodies</topic><topic>hepatitis C virus</topic><topic>Hepatitis, Chronic - therapy</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>interferon</topic><topic>Interferon alpha-2</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>NANBH</topic><topic>non-B hepatitis</topic><topic>PCR</topic><topic>Polymerase Chain Reaction</topic><topic>Recombinant Proteins</topic><topic>RNA, Viral - blood</topic><topic>sporadic non-A</topic><topic>viraemia</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>Viremia - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brillanti, S.</creatorcontrib><creatorcontrib>Garson, J. A.</creatorcontrib><creatorcontrib>Tuke, P. W.</creatorcontrib><creatorcontrib>Ring, C.</creatorcontrib><creatorcontrib>Briggs, M.</creatorcontrib><creatorcontrib>Masci, C.</creatorcontrib><creatorcontrib>Miglioli, M.</creatorcontrib><creatorcontrib>Barbara, L.</creatorcontrib><creatorcontrib>Tedder, R. S.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brillanti, S.</au><au>Garson, J. A.</au><au>Tuke, P. W.</au><au>Ring, C.</au><au>Briggs, M.</au><au>Masci, C.</au><au>Miglioli, M.</au><au>Barbara, L.</au><au>Tedder, R. S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of α-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: A quantitative polymerase chain reaction study</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J. Med. Virol</addtitle><date>1991-06</date><risdate>1991</risdate><volume>34</volume><issue>2</issue><spage>136</spage><epage>141</epage><pages>136-141</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><coden>JMVIDB</coden><abstract>Sera from 30 patients with community‐acquired, biopsy‐proven chronic non‐A, non‐B hepatitis (NANBH) were tested for antibodies to the C100 protein of hepatitis C virus (HCV). The 20 patients who showed reactivity in this assay were followed prospectively for 6 months, during which time seven were treated with recombinant α‐interferon. HCV RNA was detected by “nested” polymerase chain reaction (PCR) in 19 of the 20 anti‐C100‐positive sera taken at the onset of the study and also in five of the ten anti‐Cl00‐negative sera. Pretreatment viraemia levels ranged from 2 × 103 to 2 × 108HCV genomesiml. After 6 months of interferon, elevated serum alanine aminotransferase (ALT) levels had fallen to normal in four of the seven treated patients. In each case the response to interferon was accompanied by either a disappearance of or a decline (1 log to 8 log reduction) in viraemia. HCV genome titres in the three nonresponders and in the 13 untreated anti‐C100‐positive patients did not change significantly over this 6 month period. These findings confirm the aetiological role of HCV in community‐acquired NANBH and suggest that quantitative PCR will become a valuable technique for monitoring the antiviral effect of interferon and other experimental treatments.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>1716296</pmid><doi>10.1002/jmv.1890340213</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-6615 |
| ispartof | Journal of medical virology, 1991-06, Vol.34 (2), p.136-141 |
| issn | 0146-6615 1096-9071 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72094975 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Biological and medical sciences Enzyme-Linked Immunosorbent Assay Female HCV Hepacivirus - genetics Hepacivirus - immunology Hepatitis Antibodies - blood Hepatitis C - therapy Hepatitis C Antibodies hepatitis C virus Hepatitis, Chronic - therapy Human viral diseases Humans Infectious diseases interferon Interferon alpha-2 Interferon-alpha - therapeutic use Male Medical sciences Middle Aged NANBH non-B hepatitis PCR Polymerase Chain Reaction Recombinant Proteins RNA, Viral - blood sporadic non-A viraemia Viral diseases Viral hepatitis Viremia - therapy |
| title | Effect of α-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: A quantitative polymerase chain reaction study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A00%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20%CE%B1-interferon%20therapy%20on%20hepatitis%20C%20viraemia%20in%20community-acquired%20chronic%20non-A,%20non-B%20hepatitis:%20A%20quantitative%20polymerase%20chain%20reaction%20study&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Brillanti,%20S.&rft.date=1991-06&rft.volume=34&rft.issue=2&rft.spage=136&rft.epage=141&rft.pages=136-141&rft.issn=0146-6615&rft.eissn=1096-9071&rft.coden=JMVIDB&rft_id=info:doi/10.1002/jmv.1890340213&rft_dat=%3Cproquest_cross%3E72094975%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16035029&rft_id=info:pmid/1716296&rfr_iscdi=true |